Perceptive Advisors’s Pfizer PFE Stock Holding History

Perceptive Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-57,970	Closed	-$1.79M	–	192
2016 Q4	$1.79M	Buy	+57,970	New	+$1.77M	0.13%	84

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Perceptive Advisors's PFE Position: Q1 2017 in Review

Perceptive Advisors sold out of Pfizer (PFE) in Q1 2017, closing a stake of 57,970 shares — an estimated $1.79M sold.

Perceptive Advisors first reported a position in PFE in Q4 2016 and held it in 1 quarter. The position peaked at $1.79M in Q4 2016. 2,075 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Perceptive Advisors reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
Perceptive Advisors sold 57,970 Pfizer shares in Q1 2017, an estimated $1.79M.
Perceptive Advisors first reported a position in Pfizer in Q4 2016 and held it in 1 quarter.
Perceptive Advisors's Pfizer position peaked at $1.79M in Q4 2016.
2,075 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.